At a glance
It is estimated that it takes about seven years and visits to 10 different doctors for a patient to receive a proper diagnosis of an orphan condition. At Arphio, we partner with the best experts in the industry to identify therapeutics that are either in development or only on the market in selected countries to make them available around the globe.
Arphio is an orphan pharmaceutical company founded with the mission to improve patient access to vital treatments for rare diseases.
We believe that collaboration always yields the best results. That is why we are driven by the conviction that it is only by combining our expertise and global market reach with leading specialists in the development of orphan products that we can make vital treatments of rare diseases available to a broader population worldwide.
Although there can be multiple definitions, a disease is considered rare when it affects fewer than one in 2,000 people. That may seem like a small number, but the fact is that there are over 300 million people living with one or more of over 6,000 identified rare diseases around the world right now. Each of these is supported by family, friends and caregivers. Sadly, though, only about 5% of orphan disorders can currently be managed with an approved treatment.
Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms. We are focused on rare disease detection, market access and the supply of orphan drugs internationally.
Our mission
Rare conditions are often difficult to diagnose and so can be finding a specialist with the knowledge of treatment options for the condition be. That is why many suffering from rare diseases often feel alone. We’d like to change that, by improving patient access and awareness for vital treatments of rare diseases.
We at Arphio are solely focused on treatments for rare diseases. Our primary goal is to make these treatments accessible to a wider international population. Many treatments for rare diseases are already available, but only in certain countries.
Business Strategy
In our commitment to improve access to medication for patients with rare diseases, we are building a portfolio of innovative and effective treatments.
We specialize in the fields of genetic, hematology and oncology diseases along with other kinds of diseases where therapy is currently not widely available.
According to industry analysts, orphan drug sales worldwide as a percentage of prescription sales are expected to grow by 11.2% between 2019 and 2024, from US$128 Bn to US$217 Bn.1)
Our strategy is to partner with the best experts in the industry to identify therapeutics either in development or on the market in selected countries and make them available internationally.
1) Source Evaluate Pharma Orphan Drug Report 2020)
Partnerships
We strongly believe that good collaboration yields best results. By combining our expertise and global market reach with leading specialists in the development of orphan products, we make vital treatments to rare diseases available to a broader international population.
Our strategy is to partner with the best experts in the industry to identify therapeutics either in development or on the market in selected countries and make them available internationally.
We are open to partnerships, particularly in the fields of in-licensing, co-development, distribution and acquisitions.
Our value proposition to our partners
The multi-cultured team of over 100 qualified specialists at Arphio, comes with a broad experience in filing and launching orphan drugs in the global markets:
- A record of over 3,000 submissions of MA’s, ANDA’s and NDA’s in 70 countries.
- A wide knowledge of the different requirements of regional health care systems around the world.
- A successful track record of launching numerous orphan drugs globally.
- Leveraging cutting edge disruptive technologies that provide the company with distinct superiority that enhances the company’s performance.
- A unique bird’s-eye methodology for improved detection and diagnostics of rare diseases
- The Arphio team exercises the unique and empirical methodology of the “Six Pillars of orphan drug successful launches” that enhances the chances of a successful launch of orphan drugs for complex and rare diseases.
Join our mission
The Arphio team is driven by values and powered by technology to apply a disruptive, differentiated approach that will change the paradigm of rare disease patients’ treatment.
We are looking for partners and employees who share the same vision and embrace a futuristic approach to drive an impact on rare disease patients and caregivers globally.
Ethics, risk and compliance
Arphio operates as an independent entity that navigates the orphan global market expansion through one centralized office with a sharp focus on ethics, compliance, accessibility and corporate governance. We put great care into respecting and flawlessly implementing our partners’ compliance standards as well as our own. Above all, we strive to promote a patient-centric approach and to uphold the highest ethical and professional standards. This is crucial to our company culture and the key to our success.